Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...

In May, the FDA approved GSK’s GSK RSV vaccine, Arexvy, forthe prevention of LRTD caused by RSV in older adults aged 60+ years. This was the first RSV vaccine for older adults to be approved ...

The EU on Friday authorized the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

The advisory committee on immunizations for the Centers for DIsease Control and Prevention (CDC) voted to recommend an RSV ...

Pregnant people should get an RSV vaccine at 32 to 36 weeks’ gestation in order to protect their newborns from RSV, according ...

The FDA approved Pfizer's maternal vaccine to protect newborns from RSV. Courtesy Pfizer Still, the vaccine, given from 32 to 36 weeks of gestational age, does not provide long-term protection.

U.S. health officials are recommending RSV vaccinations for moms-to-be as a second option to protect newborns. The Centers ...

The US Centers for Disease Control and Prevention said Friday it is recommending a new vaccine to help protect babies against severe respiratory syncytial virus, or RSV. “This is another new tool we ...

Pfizer PFE announced that the European Commission has approved its new vaccine, Abrysvo, for the prevention of respiratory syncytial virus (RSV) in infants through immunization of their pregnant ...

(Reuters) -The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union. The ...

(Reuters) -The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union.